21Sep 2026
PART Trial Evaluates Partial Prostate Ablation Versus Radical Treatment for Intermediate-Risk Prostate Cancer

PART Trial Evaluates Partial Prostate Ablation Versus Radical Treatment for Intermediate-Risk Prostate Cancer

The UK-wide PART randomized controlled trial evaluates whether partial prostate ablation (PA), using high-intensity focused ultrasound (HIFU) or irreversible electroporation (IRE), provides non-inferior oncological treatment success compared with radical treatment (RT) for localized intermediate-risk prostate cancer. The study will compare treatment effectiveness, urinary and sexual side effects, health-related quality of life, serious adverse events and cost-effectiveness. The trial aims to generate prospective evidence to support treatment decision-making and evaluate whether partial ablation can offer an alternative to radical treatment.

  • #urology

Like

Save

Share